John E Edwards Jr., MD

John E Edwards Jr., MD

Professor of Medicine, David Geffen School of Medicine at UCLA
Chief, Division of Infectious Diseases, Harbor-UCLA Medical Center
Principal Scientific Co-founder and Scientific Advisor for NovaDigm Therapeutics

Contact

Pathogenesis and therapy of fungal infectious diseases

Research Description

Dr. Edwards' research focuses on understanding the cellular and molecular mechanisms of antimicrobial host defense, principally those caused by the fungus Candida, one of the most common causes of life-threatening blood infections in hospitalized patients. Dr. Edwards and his group have focused their research efforts to understand the interactions between C. albicans, endothelial cells, and immune responses. These interactions determine how Candida exploits the vascular compartment to invade deeper organ tissues. The advances made in Dr. Edwards' lab revealed specific proteins that could be used as vaccine candidates. Dr. Edwards and his team are currently optimizing the safety and efficacy of such targets as new vaccines. They have recently completed and published the first clinical trial showing a signal of efficacy in humans of an active fungal vaccine. With his work he hopes to dramatically advance the development of new anti-fungal agents and immunotherapies to prevent and treat life-threatening infections.
Theme Groups
Research Interests

Education

  • MD, 1968, University Of California, Irvine

Recent and/or Significant Publications

  1. Edwards JE, Jr, Schwartz, MM, Schmidt CS, et al. A fungal Immunotherapeutic vaccine (NDV-3A) for treatment of recurrent vulvovaginal candidiasis; A phase 2 randomized, double-blind, placebo-controlled trial. 2018, In Press, Clinical Infectious Diseases
  2. Gebremariam T, Liu M, Luo G, et al. CotH3 mediates fungal invasion of host cells during mucormycosis. J Clin Invest 2014;124:237-50. PMCID PMC3871245
  3. Liu M, Spellberg B, Phan QT, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest 2010;120:1914-24.PMCID PMC2877958
  4. Spellberg B, Ibrahim AS, Yeaman MR, et al. The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect Immun 2008;76:4574-80 PMCID PMC2546811
  5. Phan QT, Myers CL, Fu Y, et al..Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol 2007;5(3):e64. PMCID PMC1802757
  6. Ibrahim AS, Spellberg BJ, Avanesian V,et al. Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect Immun 2005;73:999-1005. PMCID PMC547099
  7. Spellberg BJ, Ibrahim AS, Avanesian V, Filler, SG, Myers CL, Fu, Y, Edwards, JE Jr. The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect Immun 2005;73(9):6191-3. PMCID PMC1231102
  8. Ibrahim AS, Spellberg B, Avanessian V, Fu Y, Edwards JE, Jr. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun 2005;73:778-83.PMCID PMC547117
  9. Phan QT. Fratti RA, Prasadarao NV, Edwards JE, Jr. Filler SG. N-cadherin mediates endocytosis of Candida albicans by endothelial cells. J Biol Chem 2005; 280:10455-61. PMID 15632157
  10. Sheppard DC, Yeaman MR, Welch WH, Phan QT, Fu Y, Ibrahim AS, Filler SG, Zhang M, Waring AJ, Edwards JE, Jr. Functional and structural diversity in the Als protein family of Candida albicans. J Biol Chem 2004;279:30480-9. PMID 15128742